Med Enclosure predicts 2005 trials for arterial closure device
This article was originally published in Clinica
Med Enclosure hopes to start in the US in the second quarter of 2005 human studies of its catheter-based system for rapidly sealing arterial puncture sites following angiography and angioplasty. The company is planning to submit to the FDA an application to begin the study under an investigational device exemption.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.